Protracted exendin-4 compounds

Details Protracted exendin-4 compounds Protracted exendin-4 compounds

2005-10-07

2011-10-04

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S006700, C514S006800, C514S021300, C530S399000, C530S324000, C530S308000

Reexamination Certificate

active

08030273

ABSTRACT:
Novel protracted exendin-4 compounds and therapeutic uses thereof.

REFERENCES:
patent: 5424286 (1995-06-01), Eng
patent: 6451970 (2002-09-01), Schaffer et al.
patent: 2001/0047084 (2001-11-01), Knudsen et al.
patent: 2004/0146985 (2004-07-01), Sun et al.
patent: 1386930 (2004-02-01), None
patent: 96/29342 (1996-09-01), None
patent: WO 98/08871 (1998-03-01), None
patent: 99/43708 (1999-09-01), None
patent: WO 99/43341 (1999-09-01), None
patent: WO 99/43706 (1999-09-01), None
patent: WO 99/43708 (1999-09-01), None
patent: WO 00/34331 (2000-06-01), None
patent: WO 00/55119 (2000-09-01), None
patent: 00/66629 (2000-11-01), None
patent: 00/69911 (2000-11-01), None
patent: 01/04156 (2001-01-01), None
patent: WO 01/98331 (2001-12-01), None
patent: 02/46227 (2002-06-01), None
patent: WO 03/002136 (2003-01-01), None
patent: WO 03/011892 (2003-02-01), None
patent: WO 2004/005342 (2004-01-01), None
patent: WO 2004/089985 (2004-10-01), None
patent: WO 2005/027978 (2005-03-01), None
patent: WO 2006/037810 (2006-04-01), None
patent: WO 2006/051103 (2006-05-01), None
patent: WO 2006/097535 (2006-09-01), None
patent: WO 2006/097537 (2006-09-01), None
patent: WO 2006/097538 (2006-09-01), None
Holz, G.G. et al, Glucagon Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus, Current Medicinal Chemistry, 2003, 2471-2483, vol. 10—No. 22, Bentham Science Publishers.
Knudsen, L.B., Potent Derivatives of Glucagon-Like Peptide-1 With Pharmacokinetic Properties Suitable for Once Daily Administration, Journal of Medicinal Chemistry, vol. 43(9), 1664-9 (2000).
Knudsen, L.B., Glucagon-Like Peptide-1: The Basis of a New Class of Treatment for Type-2 Diabetes, Journal of Medicinal Chemistry, vol. 47(17), pp. 4128-4134 (2004).
Adelhorst, K. et al., Structure-Activity Studies of Glucagon-Like Peptide-1, Journal of Biological Chemistry, vol. 269(9), pp. 6275-6278 (1994).
Deacon, C.F. et al., Dipeptidyl Peptidase IV Resistant Analogues of Glucagon-Like Peptide-1 Which Have Extended Metabolic Stability and Improved Biological Activity, Diabetologia, vol. 41, pp. 271-278 (1998).
Green, B.D. et al., Degradation Receptor Binding Insulin Secreting and Antihype Glycaemic Actions of Palmitate-Derivatised Native and ALA-Substituted GLP-1 Analogues, Biol. Chem., vol. 385(2), pp. 169-177 (2004).
Green, B.D. et al., N-Terminal IIIS-Modification of Glucagon-Like Peptide-1 (7-36) Amide Generates Dipeptidyl Peptidse IV-Stable Analogues With Potent Antihyperglycaemic Activity, Journal of Endocrinology, vol. 180(3), pp. 379-388 (2004).
Gallwitz, B. et al., GLP-1 Analogues Resistant to Degradation by Dipeptidyl-Peptidase IV In Vitro, Regulatory Peptides, vol. 86(1-3), pp. 103-111 (2000).
Office Action in U.S. Appl. No. 11/664,788 (Lau et al., filed Apr. 5, 2007), mailed from the USPTO on Jun. 2, 2009.
Final Office Action in U.S. Appl. No. 11/664,788 (Lau et al., filed Apr. 5, 2007), mailed from the USPTO on Mar. 3, 2010.

Affiliated with

Also associated with

Rating

Protracted exendin-4 compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protracted exendin-4 compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protracted exendin-4 compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4277986